Egis Sees Sales Rising as Much as 6% Next Year, MTI Reports

Egis (EGIS) Nyrt., the Hungarian drugmaker owned by Laboratoires Servier, expects revenue growth to pick up next year on accelerating exports, state news service MTI said, citing Chief Financial Officer Csaba Poroszlai.

Total revenue probably will increase between 4 percent and 6 percent next year in forint terms after a projected sales growth of between 3 percent to 5 percent this year, Poroszlai said, according to MTI.

Domestic sales are expected to drop as much as 10 percent in the 2012/2013 fiscal year, while exports to the Commonwealth of Independent States are set to grow between 8 percent and 12 percent, similarly to Russian sales, Poroszlai said, MTI reported.

To contact the reporter on this story: Edith Balazs in Budapest at

To contact the editor responsible for this story: James M. Gomez at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.